Assessment of the efficacy of tilmicosin phosphate to eliminate Actinobacillus pleuropneumoniae from carrier pigs.
The aim of this study was to evaluate the efficacy of in-feed medication with tilmicosin phosphate in order to eliminate or reduce the carriage of Actinobacillus pleuropneumoniae in the tonsils of carrier pigs. Two groups of 6 carrier animals received either a non-medicated feed (control group) or feed medicated with 400 ppm of tilmicosin phosphate (treated group) for 30 d. Three sentinel pigs were then introduced in each group and left for 29 d. The presence of A. pleuropneumoniae in tonsils was monitored using several techniques, including polymerase chain reaction (PCR). At the end of the treatment all of the control animals, but only 1 treated pig, were positive by PCR from tonsillar surface material. However, at necropsy, all control and most treated animals, as well as 1 sentinel animal, in both groups were positive by PCR from whole tonsils. In conclusion, under the experimental conditions, in-feed treatment with 400 ppm of tilmicosin phosphate significantly reduced the presence of A. pleuropneumoniae on the surface of tonsils but was unable to completely eliminate the organism from deeper tonsillar tissues and to prevent bacterial shedding by carrier animals.
Fittipaldi
N
N
Groupe de recherche sur les maladies infectieuses du porc, Faculté de médecine vétérinaire, Université de Montreal, 3200 Sicotte, CP 5000, St-Hyacinthe, Quebec.
Klopfenstein
C
C
Gottschalk
M
M
Broes
A
A
Paradis
M A
MA
Dick
C P
CP
D000189:Actinobacillus Infections / Q000188:drug therapy / Q000517:prevention & control / Q000662:veterinary*; D016977:Actinobacillus pleuropneumoniae / Q000187:drug effects* / Q000254:growth & development; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002353:Carrier State / Q000188:drug therapy / Q000517:prevention & control / Q000662:veterinary*; D018942:Macrolides / Q000494:pharmacology / Q000627:therapeutic use*; D014066:Palatine Tonsil / Q000382:microbiology; D011897:Random Allocation; D013552:Swine; D013553:Swine Diseases / Q000188:drug therapy* / Q000517:prevention & control; D016896:Treatment Outcome; D015645:Tylosin / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D018942:Macrolides; C052319:tilmicosin; D015645:Tylosin